In vitro and in vivo safety evaluation of the bacteriocin producer Streptococcus macedonicus ACA-DC 198

dc.contributor.author	Maragkoudakis, PA	en
dc.contributor.author	Papadelli, M	en
dc.contributor.author	Georgalaki, M	en
dc.contributor.author	Panayotopoulou, EG	en
dc.contributor.author	Martinez-Gonzalez, B	en
dc.contributor.author	Mentis, AF	en
dc.contributor.author	Petraki, K	en
dc.contributor.author	Sgouras, DN	en
dc.contributor.author	Tsakalidou, E	en
dc.date.accessioned	2014-06-06T06:49:26Z
dc.date.available	2014-06-06T06:49:26Z
dc.date.issued	2009	en
dc.identifier.issn	01681605	en
dc.identifier.uri	http://dx.doi.org/10.1016/j.ijfoodmicro.2009.05.012	en
dc.identifier.uri	http://62.217.125.90/xmlui/handle/123456789/4596
dc.subject	Murine model	en
dc.subject	Pathogenicity	en
dc.subject	Safety	en
dc.subject	Streptococcus macedonicus	en
dc.subject.other	ampicillin	en
dc.subject.other	bacterial protein	en
dc.subject.other	bacteriocin	en
dc.subject.other	chloramphenicol	en
dc.subject.other	ciprofloxacin	en
dc.subject.other	erythromycin	en
dc.subject.other	kanamycin	en
dc.subject.other	protein emm	en
dc.subject.other	protein hasA	en
dc.subject.other	protein hylA	en
dc.subject.other	protein hylP2	en
dc.subject.other	protein mga	en
dc.subject.other	protein sagAB	en
dc.subject.other	protein ScpA	en
dc.subject.other	protein ska	en
dc.subject.other	protein slo	en
dc.subject.other	protein smez2	en
dc.subject.other	protein Speb	en
dc.subject.other	protein speF	en
dc.subject.other	protein speg	en
dc.subject.other	protein speJ	en
dc.subject.other	streptomycin	en
dc.subject.other	tetracycline	en
dc.subject.other	unclassified drug	en
dc.subject.other	vancomycin	en
dc.subject.other	animal behavior	en
dc.subject.other	animal experiment	en
dc.subject.other	animal health	en
dc.subject.other	animal model	en
dc.subject.other	animal tissue	en
dc.subject.other	antibiotic resistance	en
dc.subject.other	antibiotic sensitivity	en
dc.subject.other	article	en
dc.subject.other	bacterial metabolism	en
dc.subject.other	bacterial strain	en
dc.subject.other	bacterial viability	en
dc.subject.other	bacterial virulence	en
dc.subject.other	bacterium examination	en
dc.subject.other	controlled study	en
dc.subject.other	DNA DNA hybridization	en
dc.subject.other	feces culture	en
dc.subject.other	fluid intake	en
dc.subject.other	gastritis	en
dc.subject.other	gastrointestinal tract	en
dc.subject.other	Greece	en
dc.subject.other	hemolysis	en
dc.subject.other	histopathology	en
dc.subject.other	in vitro study	en
dc.subject.other	in vivo study	en
dc.subject.other	male	en
dc.subject.other	minimum inhibitory concentration	en
dc.subject.other	mouse	en
dc.subject.other	nonhuman	en
dc.subject.other	nucleotide sequence	en
dc.subject.other	polymerase chain reaction	en
dc.subject.other	safety	en
dc.subject.other	Streptococcus	en
dc.subject.other	Streptococcus macedonicus	en
dc.subject.other	Streptococcus pyogenes	en
dc.subject.other	weight gain	en
dc.subject.other	wellbeing	en
dc.subject.other	Animals	en
dc.subject.other	Anti-Bacterial Agents	en
dc.subject.other	Bacterial Translocation	en
dc.subject.other	Bacteriocins	en
dc.subject.other	Cheese	en
dc.subject.other	Drug Resistance, Microbial	en
dc.subject.other	Food Microbiology	en
dc.subject.other	Genes, Bacterial	en
dc.subject.other	Male	en
dc.subject.other	Mice	en
dc.subject.other	Mice, Inbred C57BL	en
dc.subject.other	Microbial Sensitivity Tests	en
dc.subject.other	Phenotype	en
dc.subject.other	Streptococcus	en
dc.subject.other	Virulence	en
dc.subject.other	Animalia	en
dc.subject.other	Hyla	en
dc.subject.other	Murinae	en
dc.subject.other	Mus	en
dc.subject.other	Streptococcus macedonicus	en
dc.subject.other	Streptococcus pyogenes	en
dc.title	In vitro and in vivo safety evaluation of the bacteriocin producer Streptococcus macedonicus ACA-DC 198	en
heal.type	journalArticle	en
heal.identifier.primary	10.1016/j.ijfoodmicro.2009.05.012	en
heal.publicationDate	2009	en
heal.abstract	Streptococcus macedonicus ACA-DC 198, a bacteriocin producer isolated from Greek Kasseri cheese, was used in a series of in vitro and in vivo experiments in order to evaluate its pathogenic potential. The strain was examined in vitro for haemolytic activity, antibiotic resistance and presence of pathogenicity genes encountered in Streptococcus pyogenes. Subsequently, the strain was orally administered to mice (8.9 log cfu daily), continuously over a period of 12 weeks, in order to ascertain the effects of its long term consumption on animal health and gastric inflammation. S. macedonicus ACA-DC 198 was found to be non-haemolytic and sensitive to ampicillin, chloramphenicol, ciprofloxacin, erythromycin, streptomycin, tetracycline, and vancomycin, with the only resistance observed against kanamycin. PCR amplification and DNA-DNA hybridization did not reveal the presence of any of the S. pyogenes pathogenicity genes examined, namely emm, scpA, hasA, speB, smez2, speJ, sagAB, hylA, ska, speF, speG, slo, hylP2 and mga. In the mouse study, no detrimental effects were observed in the behaviour, general well being, weight gain and water consumption of the animals receiving S. macedonicus ACA-DC 198. Histologic analysis showed no evidence of inflammation in the stomach of the animals receiving S. macedonicus ACA-DC 198, while faecal microbiological analysis revealed that the strain retained its viability passing through the mouse gastrointestinal tract. Finally, no evidence of translocation to the liver, spleen and mesenteric lymph nodes was observed. In conclusion, none of the examined virulence determinants were detected in S. macedonicus ACA-DC 198 and its long term, high dosage oral administration did not appear to induce any pathogenic effect in mice. © 2009 Elsevier B.V. All rights reserved.	en
heal.journalName	International Journal of Food Microbiology	en
dc.identifier.issue	1-2	en
dc.identifier.volume	133	en
dc.identifier.doi	10.1016/j.ijfoodmicro.2009.05.012	en
dc.identifier.spage	141	en
dc.identifier.epage	147	en